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Many soft tissue tumors recapitulate features of normal connective tissue. We hypothesize that different types of
fibroblastic tumors are representative of different populations of fibroblastic cells or different activation states of
these cells. We examined two tumors with fibroblastic features, solitary fibrous tumor (SFT) and desmoid-type
fibromatosis (DTF), by DNA microarray analysis and found that they have very different expression profiles, including
significant differences in their patterns of expression of extracellular matrix genes and growth factors. Using
immunohistochemistry and in situ hybridization on a tissue microarray, we found that genes specific for these two
tumors have mutually specific expression in the stroma of nonneoplastic tissues. We defined a set of 786 gene spots
whose pattern of expression distinguishes SFT from DTF. In an analysis of DNA microarray gene expression data from
295 previously published breast carcinomas, we found that expression of this gene set defined two groups of breast
carcinomas with significant differences in overall survival. One of the groups had a favorable outcome and was defined
by the expression of DTF genes. The other group of tumors had a poor prognosis and showed variable expression of
genes enriched for SFT type. Our findings suggest that the host stromal response varies significantly among
carcinomas and that gene expression patterns characteristic of soft tissue tumors can be used to discover new markers
for normal connective tissue cells.
Citation: West RB, Nuyten SA, Subramanian S, Nielsen TO, Corless CL, et al. (2005) Determination of stromal signatures in breast carcinoma. PLoS Biol 3(6): e187.
Introduction
Numerous soft tissue tumors demonstrate speciﬁc differ-
entiation toward connective tissue [1]. This may be repre-
sented in cytoplasmic organelles or extracellular matrix
deposition, or deﬁned by immunohistochemical features.
Some soft tissue tumors have features of smooth muscle cells
(leiomyomas, leiomyosarcomas) or adipocytes (lipoma, lip-
osarcoma). Other soft tissue tumors exhibit features of rarer
cell types such as the interstitial cell of Cajal (gastrointestinal
stromal tumor) and glomus cells (glomus tumor). There are
numerous tumors with ﬁbroblastic and myoﬁbroblastic
features, but their corresponding normal counterparts are
not well delineated by available markers. We examined two
ﬁbroblastic tumors: solitary ﬁbrous tumor (SFT) and des-
moid-type ﬁbromatosis (DTF). Both tumors are composed of
spindled cells, typically have low-grade nuclear morphology,
and can occur throughout the body. Most SFTs occur on the
pleural surface, but they have been recognized in a wide
range of anatomic locations. Although they were initially
thought to be associated with mesothelial differentiation, a
number of studies have indicated that SFTs are derived from
ﬁbroblasts [2–4]. The vast majority of SFTs are CD34
immunoreactive [5]. SFTs do not generally inﬁltrate into
surrounding soft tissue, recur after excision, or metastasize.
However, a minority of cases exhibit malignant features [6]
and these are associated with chromosomal alterations [7].
DTF is widely assumed to be derived from ﬁbroblasts of the
deep soft tissue. DTFs occur both sporadically or as part of a
syndrome due to germline APC mutations in familial
adenomatous polyposis coli. These tumors are often found
in the deep soft tissue of the trunk or abdomen. The sporadic
DTFs also often have mutations in APC or b-catenin [8],
suggesting that abnormal activation of the canonical Wnt
pathway plays a role in their pathogenesis. Sporadic and
familial DTFs have been found to be composed of a
monoclonal population [9,10]. DTFs are locally aggressive
and are difﬁcult to resect completely: local recurrences in
anatomically critical sites can be fatal.
Thus SFT and DTF show signiﬁcant differences in clinical
behavior. Although the histologic growth patterns are
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growth than SFT, the individual cells that comprise these
tumors are histologically very similar and hard to distinguish.
As such, these two tumors form a good model system to use
for discovery of novel connective tissue markers.
In this study, we used DNA microarrays to proﬁle gene
expression of two ﬁbroblastic tumors, DTF and SFT. The
gene expression proﬁles deﬁne two different ﬁbroblastic
neoplasms that may correspond to two physiologic ﬁbroblas-
tic phenotypes or ﬁbroblastic response patterns. We demon-
strate that several genes differentially expressed in DTF and
SFT are also differentially expressed in characteristic
patterns in conditions from inﬂammatory and reparative
tissue to neoplasia. The interaction between tumor cells and
Figure 1. Soft Tissue Tumor Gene Expression
Unsupervised hierarchical clustering of ten cases of DTF (blue), 13 cases of SFT (orange), and 35 other previously examined soft tissue tumors
(black) based on expression proﬁling on 42,000-element cDNA microarrays. Red represents high expression, black represents median
expression, green represents low expression, and grey represents no data. Gene array data are available at http://microarray-pubs.stanford.edu/
tma-portal/DTF_SFTbreast.
DFSP, dermatoﬁbrosarcoma protuberans; GIST, gastrointestinal stromal tumor; LMS, leiomyosarcomas, MFH, malignant ﬁbrous histiocytomas;
SS, synovial sarcoma.
DOI: 10.1371/journal.pbio.0030187.g001
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Stromal Signatures in Breast Carcinomasurrounding stroma has been the subject of many studies.
Here we show that gene sets discovered in ﬁbroblastic tumors
can be used to recognize prognostically distinct subsets of
breast carcinomas.
Results
Expression Profiling Comparison of SFT and DTF
The ten cases of DTF and 13 cases of benign SFT were
compared to 35 other previously examined soft tissue tumors
[11,12] with expression proﬁling on 42,000-element cDNA
microarrays, corresponding to approximately 36,000 unique
gene sequences. Unsupervised hierarchical cluster analysis
organized the 58 tumors and the 3,778 gene spots that
demonstrate at least 4-fold variation from the mean in at least
two tumors (see Materials and Methods). Based on gene
expression, all the DTF and SFT cases can be separated into
two groups according to the pathologic diagnosis. The two
ﬁbroblastic tumors did not group together. Instead, the SFTs
clustered on the same branch as synovial sarcoma and
gastrointestinal stromal tumor, whereas the DTF cases
clustered on the same branch as the majority of leiomyo-
sarcomas, dermatoﬁbrosarcoma protuberans, and malignant
ﬁbrous histiocytomas (Figure 1).
Comparison of Expression Patterns in SFT and DTF
To directly compare the expression patterns, the ten cases
of DTF and 13 cases of SFT were analyzed without the other
soft tissue tumors. Using the same ﬁltering criteria as above,
the 23 tumors were clustered based on 1,010 gene spots.
Again, the tumors clustered according to pathologic diag-
nosis (see Figure S1). The dataset was analyzed using the
signiﬁcance analysis of microarray (SAM) method [13] to
create two lists. The two lists included genes signiﬁcantly
more highly expressed in either SFT or DTF. A total of 786
gene spots, differentially expressed between the two tumor
types, had a false discovery rate of one in 786 (0.13%). The
SFT-speciﬁc gene list shared 64% identity with a list of genes
selected using SAM for speciﬁc expression in SFT compared
to all other soft tissue tumors in the initial set of 58 soft tissue
tumors. Likewise, the DTF-speciﬁc gene list shared 65%
identity with a list selected by SAM based on differential
expression in DTF compared with the 58 soft tissue tumors.
The two tumor types differed in their patterns of
expression in a number of different functional categories of
genes (Tables 1 and S1). On the basis of these differences in
expression, we hypothesize that the cells of origin for each
lesion may perform different functions in normal connective
tissue. One of the more striking differences is in the variation
of genes involved in ﬁbrotic response and basement
membrane synthesis between the two tumors. DTF has high
expression of genes involved in the ﬁbrotic response. These
include numerous collagen genes, such as COL1A1 and
COL3A1, involved in ﬁbrosis and contraction and a number
of growth factors that stimulate the classic ﬁbrotic response.
DTFs also highly express numerous genes that remodel the
extracellular matrix, including ADAM and MMP family
members, consistent with its inﬁltrative behavior. In contrast,
SFTs highly express collagen genes and other genes involved
in basement membrane formation and maintenance, such as
COL4A5 and COL17A1. In contrast to DTF, no metallopro-
teinase family members were especially highly expressed in
SFTs. Possible exceptions were ADAM22 and ADAM23, which
were highly expressed in SFT. But the metalloprotease
domain is inactive in these proteins, and these proteins are
Table 1. Selected Genes in DTF (Group A) and SFT (Group B)
Category Extracellular Matrix Growth Factor Pathways WNT Pathway
Symbol UGCluster LLID Symbol UGCluster LLID Symbol UGCluster LLID
Selected fibromatosis genes COL1A1 Hs.172928 1277 TGFB2 Hs.133379 7042 FZD1 Hs.94234 8321
COL5A1 Hs.210283 1289 TGFB3 Hs.2025 7043 FZD2 Hs.142912 2535
COL3A1 Hs.443625 1281 CTGF Hs.410037 1490 DKK2 Hs.211869 27123
COL6A1 Hs.474053 1291 FGF11 Hs.528468 2256 DKK3 Hs.292156 27122; 10530
COL8A1 Hs.134830 1295 FGF12 Hs.185577 2257 WISP1 Hs.492974 8840
FBN1 Hs.146447 2200 WISP2 Hs.194679 8839
TPM1 Hs.133892 7168 WNT5A Hs.152213 7474
MYL9 Hs.504687 10398
MYO10 Hs.481720 4651
CNN1 Hs.465929 1264
CALD1 Hs.490203 800
ADAM12 Hs.386283 8038
ADAM19 Hs.483944 8728; 26999
ADAMTS1 Hs.534115 9510
MMP11 Hs.143751 4320
MMP19 Hs.154057 4327
MMP23b Hs.211819 8510; 8511
Selected SFT genes COL4A5 Hs.369089 1287 NRG2 Hs.408515 9542
COL17A1 Hs.117938 1308 ERBB2 Hs.446352 2064
COL21A1 Hs.47629 81578 EPS8 Hs.26139 2059
CDH24 Hs.155912 64403 DDR1 Hs.520004 780
SPOCK Hs.124611 6695 MERTK Hs.306178 10461
SPOCK3 Hs.481133 50859 IGF1 Hs.160562 3479
DTF and SFT were analyzed by SAM (see Materials and Methods) resulting in 786 genes with fewer than 0.1% false positive genes. Entire gene list is available at http://microarray-pubs.stanford.edu/tma-portal/DTF_SFTbreast.
DOI: 10.1371/journal.pbio.0030187.t001
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remodeling. SFTs highly express a number of signaling
pathways involved in growth and survival, including BCL2
and IGF1. DTF and SFT also differed in other pathways,
including WNT signaling and THY1 expression. Thus,
although SFT and DTF both express genes typically expressed
in ﬁbroblasts, they express genes that belong to very different
functional groups.
Histologic Patterns of Expression of Genes Characteristic
of SFT and DTF
To conﬁrm, localize, and extend our observations on the
expression of DTF- and SFT-speciﬁc genes, we constructed a
tissue microarray (TMA) and measured expression using
immunohistochemistry (IHC) and in situ hybridization (ISH;
see Materials and Methods). The TMA contained representa-
tive cores of ﬁve DTFs and SFTs, in addition to cores of scar
and keloid. In addition, the TMA included well-oriented
embedded pieces of normal skin, lung, and breast tissue
(Figure S2). The array also contained 11 ﬁbroadenomas, as
well as ﬁve colorectal and 24 breast carcinomas.
SFTs, ﬁbroadenomas, and a subset of normal ﬁbroblasts in
the skin and breast specimens demonstrated expression of
SFT-speciﬁc genes (Figures 2, 3, and S3). Normal ﬁbroblasts
that reacted for SFT markers, APOD and CD34, included
those associated with adnexal glands and dermal fat. The
reactivity of so-called dendritic interstitial cells for CD34 in a
number of locations was previously reported [14]. These
tissues were rarely positive for DTF-speciﬁc gene probes.
DTF-speciﬁc probes, for OSF2 and CTHRC1, were positive in
DTF, keloid, scar, granulation tissue, and ﬁstula tract (Figures
2 and 3). In the granulation tissue and ﬁstula tract tissue, a
gradient of expression dependent on location of the cells
within the tissue could be identiﬁed in some hybridizations.
There was no staining of ﬁbroblast-like cells by probes for
OSF2 and CTHRC1 in the normal tissues.
A similar pattern of differential expression of SFT and DTF
markers was observed in breast carcinoma. With the
exception of APOD, only stromal staining was observed with
these markers whereas the neoplastic epithelial cells did not
react. For breast carcinoma, 24 cases were scored for stromal
staining (see Materials and Methods) and clustered by
hierarchical clustering. The resulting dendrogram and
heatmap are shown in Figure 4. A subset of cases was positive
for the SFT markers, CD34 and APOD, another for the DTF
markers, OSF2 and CTHRC1.
Variable Expression of Genes Characteristic of Fibroblastic
Tumors in Breast Carcinoma
To further investigate the implication of the variation in
expression of these ﬁbroblastic tumor-related genes in breast
cancer, we analyzed their expression in 295 breast carcinomas
using a previously published dataset. We focused on the genes
selected by SAM for differential expression in DTF versus
SFT, and investigated their expression levels in the published
breast cancer dataset (see Materials and Methods).
When clustering the breast carcinomas with the ﬁbroblastic
tumor-related genes only, the resulting dendrogram of the
tumors/samples showed several high-order branches of
correlation between distinct tumor groups. Two of these
groups (Figure 5, groups A and B) showed remarkable
differences in the expression of DTF versus SFT genes.
Tumor group A, composed of 120 breast carcinomas, showed
high levels of expression of a gene cluster (gene cluster 1, left
sidebar) highly enriched for genes that are found in DTF (see
right sidebar: genes highly expressed in DTF are represented
by purple). This gene cluster was predominately composed of
genes whose protein products interact with the extracellular
matrix, including collagens, cadherins, and remodeling
enzymes. Moreover, two key growth factors in the ﬁbrotic
response were also identiﬁed, TGFB3 and CTGF. The second
tumor group (group B), composed of 59 breast carcinomas,
showed expression of a mixture of genes (gene cluster 2, left
sidebar) that were enriched for those genes that positively
identiﬁed SFT (see right sidebar: genes highly expressed in
SFT are represented by pink). This gene cluster contained
extracellular matrix-interacting genes, such as COL9A3 and
ADAMTS1. An additional cluster (gene cluster 3, left sidebar),
containing a mixture of SFT and DTF genes, was predom-
Figure 2. Localization of Fibroblastic Gene Expression
Comparison of expression of two SFT markers APOD (ISH) and CD34
(IHC), and two DTF markers CTHRC1 (ISH) and OSF2 (ISH) in SFT
and DTF. SFTs express ApoD and CD34 whereas DTFs express
CTHRC1 and OSF2. H&E, hematoxylin-eosin. Magniﬁcation = 6003.
DOI: 10.1371/journal.pbio.0030187.g002
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tumor group B.
The prognosis of these two tumor groups, (A and B), was
assessed by distant metastasis-free survival and overall
survival (Figure 6). Group A demonstrated signiﬁcantly better
outcomes in both overall survival (80% at 10 y vs. 63%; p =
0.0009) and metastasis-free survival (77% at 10 y vs. 58%; p =
0.002) as compared to the all tumors. In contrast, group B
demonstrated signiﬁcantly poorer outcome in overall survival
(45% at 10 y vs. 76%; p , 0.00001) and distant metastasis-free
survival (50% at 10 y vs. 69%; p = 0.002) compared to all
other tumors.
For both tumor groups A and B, prognostic performance
was independent in multivariate analysis for clinical risk
factors including tumor size, lymph node status, and tumor
grade (see Table 2). The hazard ratio for death was 2.6 (1.6–
4.4, 95% conﬁdence interval [CI]) for group B and 0.55 (0.33–
0.92, 95% CI) for group A. Group B also retained
independent prognostic relevance when the previously
described 70-gene prognosis proﬁle [15] is considered in
the model.
Discussion
Expression patterns among ﬁbroblasts in tumors/carcino-
mas in vivo are difﬁcult to assess due to tissue heterogeneity,
which includes the relative content of epithelial cells, vascular
structures, and inﬂammatory cells, and the diversity of
ﬁbroblastic and myoﬁbroblastic cells that may be present.
We have attempted to gain insight into the possible variation
in expression patterns in ﬁbroblastic cells by examining two
ﬁbroblastic neoplasms, SFT and DTF.
Soft tissue tumors are comprised of relatively pure
populations of cells in comparison with other tissue types,
including normal tissues and other neoplasms [16]. Thus, the
gene expression proﬁle of a soft tissue tumor represents
primarily a single cell type. To a degree, many soft tissue
tumors recapitulate normal tissue components both morpho-
logically and by protein expression, and this is the basis for
much of the diagnostic nomenclature in surgical pathology.
Interactions between carcinoma and host tissue have long
been recognized. Many studies have demonstrated the
importance of vascular recruitment and inﬂammatory re-
sponse in tumorigenesis. The role that ﬁbroblastic cells play
in carcinoma has been less well deﬁned. In part, this problem
arises from our limited understanding of ﬁbroblast subtypes
and/or ﬁbroblast activation states. Past studies have noted the
presence of a ‘‘ﬁbroblast signature’’ in carcinoma [17] and
other studies have demonstrated topographical variation in
ﬁbroblast gene expression in vitro [18].
Two previous studies have examined the gene expression
proﬁles for stromal cells in the context of carcinoma. One
study examined the gene expression progression in cultured
primary ﬁbroblasts in response to serum exposure [19]. This
expression program included many features suggestive of a
wound response [20]. Tissue localization studies demonstra-
ted that in carcinomas, most of these ‘‘wound-response’’
genes were expressed by the tumor and stromal cells,
although some were expressed by tumor cells, and some by
Figure 3. Fibroblastic Markers in Non-Neoplastic Tissue
(A) Skin adnexa, (B) breast, (C) dermis, (D) reactive, and (E) keloid tissue arranged in rows. Fibroblastic markers: CD34 (IHC), APOD (ISH),
CTHRC1 (ISH) and OSF2 (ISH) arranged in columns. SFTs express APOD and CD34 whereas DTFs express CTHRC1 and OSF2. Magniﬁcation =
6003. (A magniﬁcation of 3003 is shown in Figure S3.)
DOI: 10.1371/journal.pbio.0030187.g003
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strongly predictive of metastasis and progression for a variety
of carcinomas. There is no signiﬁcant overlap between the
genes in the ‘‘serum-response’’ signature and the genes we
report here to be associated with either SFT or DTF. A
follow-up study [21] demonstrated that the serum-response
signature was an independent predictor of outcome in the
same dataset of 295 breast carcinomas currently studied.
When compared to the 509 unique gene sequences of the
serum-response signature applied to the NKI (Nederlands
Kanker Instituut [Netherlands Cancer Institute]) breast
carcinoma dataset [21], there are only 15 matches to the
SFT/DTF gene list. The lack of overlap makes sense as the
experimental approach between the two lists is fundamen-
tally different. The serum-response signature looks at the
effects of serum on cells and whether the resulting gene
expression pattern could be seen in cancer. The Chang et al.
study [19] used cultured ﬁbroblasts as a detection system for
serum response, but in breast carcinomas most of the genes
thus identiﬁed were expressed in both tumor and stromal
cells. In this study we searched for genes expressed by
‘‘ﬁbroblastic tumors’’ with the aim of gaining insight into
stromal cells within tumors.
A second study used serial analysis of gene expression on
sorted components of the breast cancer microenvironment
[22]. The authors used antibody beads to separate the cancer
tissue into ﬁve categories: ‘‘epithelial cells,’’ ‘‘leukocytes,’’
‘‘myoepithelium/myoﬁbroblasts,’’ ‘‘endothelium,’’ and ‘‘stro-
ma.’’ Interestingly, a number of genes were found to be highly
expressed in their ‘‘myoepithelial/myoﬁbroblast’’ cell pop-
ulation that are also present in our ﬁbromatosis gene list,
including COL1A1, MMP11, and CTHRC1. However, that
study only examined three invasive breast carcinomas and did
not report on prognostic signiﬁcance.
We hypothesized that tumors with different ﬁbroblastic
features might represent different activation states or differ-
ent subtypes of normal ﬁbroblasts or stromal cells. Thus, we
examined two tumors with ﬁbroblastic differentiation: SFT
and DTF. These two tumors have been extensively studied by
morphology, IHC, and electron microscopy and are known to
share features with non-neoplastic ﬁbroblasts [1–4]. In this
study we demonstrate that the gene expression patterns of
these two tumors are distinguished by differences in
expression of a variety of functional groups of genes. DTF
expresses numerous collagens that are present in a ﬁbrotic
response. Numerous myoﬁbroblastic genes are also expressed
by DTF. In contrast, SFTs express collagens and other
extracellular matrix proteins that are typically found in the
basement membrane. DTF tumors express several genes in
the ADAM and MMP families involved in extracellular matrix
remodeling, which might be relevant to the more inﬁltrative
behavior of these tumors. SFTs expresses few of these genes,
and the ADAMs that are expressed in SFT (ADAM22 and
ADAM23) are probably involved more in cell adhesion than in
extracellular matrix remodeling. In addition, DTF tumors
express growth factors involved in the proﬁbrotic response,
such as TGFB and CTGF.
By IHC and ISH, markers representative of the separate
DTF and SFT gene sets highlighted at least two groups of
normal connective tissue ‘‘ﬁbroblasts’’ or stromal cells. The
cells positive for DTF markers are found in a variety of
reactive tissues, ranging from inﬂammatory granulation
tissue to scar tissue. In contrast, cells positive for SFT
markers tend to be found in normal tissue. The stromal cells
surrounding breast lobules and eccrine lobules of the skin
were strongly reactive for SFT markers and negative for DTF
genes. These ﬁndings are consistent with the gene expression
data in which SFTs highly express many genes that help
create basement membrane.
We created two gene sets consisting of genes that are
positively identiﬁed either as DTF or SFT. For four genes we
determined the expression patterns in breast carcinoma
samples and showed that they were restricted to connective
tissue cells and were not expressed by tumor cells. With these
gene sets, we can evaluate for the presence of an expression
signature of either SFT or DTF in other gene array datasets.
In this study, we examined a previously published breast
carcinoma dataset that contains 295 tumors with a median
follow-up of 7.8 y [15]. These gene sets highlight a minor
expression pattern within a gene expression dataset that may
Figure 4. Fibroblast Markers in Breast Carcinoma
(A) Examples of SFT (APOD [ISH] and CD34 [IHC]) and DTF
(CTHRC1 [ISH] and OSF2 [ISH]) expression in breast carcinoma
stroma. Each panel shows expression of the marker that is restricted
to the ﬁbroblasts between neoplastic cells. Magniﬁcation = 6003.
(B) Hierarchical clustering of 24 breast carcinomas based on TMA
staining with ﬁbroblast markers: CD34 (IHC), APOD (ISH), CTHRC1
(ISH), and OSF2 (ISH). Bright red represents high expression, dull red
represents intermediate high expression, green represents negative
expression, and white represents no data. The DTF-associated cluster
is highlighted in blue. The SFT-associated cluster is highlighted in
orange. Most breast carcinomas express either a DTF or SFT gene in
the stromal ﬁbroblasts. However, some breast carcinomas express a
combination of DTF and SFT genes, and some express neither.
DOI: 10.1371/journal.pbio.0030187.g004
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In this case, the expression pattern is putatively associated
with stromal ﬁbroblast-like cells, a cell population that is
often the minority in breast carcinoma and may not have as
much RNA expression. Thus, we might expect the expression
signature of stromal cells to be obscured in the hierarchical
clustering of the entire dataset.
When the breast carcinoma dataset was analyzed with the
SFT and DTF gene sets, three main gene clusters were
apparent, one more tightly correlated than the other two.
The ﬁrst gene cluster (see Figure 5, gene cluster 1) was
composed almost entirely of DTF genes. Most of these genes
are involved in stimulating or interacting with the extrac-
ellular matrix in a pro-ﬁbrotic manner. This gene cluster
identiﬁed a tumor cluster of 120 cases (tumor group A).
Tumor group B showed a less-obvious relationship to either
of the soft tissue tumors. However, it was deﬁned by two gene
clusters enriched for SFT genes, either by high expression for
the genes (gene cluster 2) or relatively low expression for
these genes (gene cluster 3). Interestingly, the two tumor
groups had very different clinical behaviors. Tumor group A
had a statistically signiﬁcant better overall survival and
metastasis-free survival when compared to the rest of the
dataset. In contrast, tumor group B had a statistically
signiﬁcant worse overall survival and metastasis-free survival
when compared to the rest of the dataset. In multivariate
analysis this predictive value is independent of clinico-
pathological risk factors. These ﬁndings show that stromal
expression patterns can vary amongst breast carcinomas and
may be clinically signiﬁcant.
In summary, analysis of gene expression patterns in two
soft tissue tumors, DTF and SFT, has allowed identiﬁcation of
at least two different nonneoplastic subtypes of stromal cells.
Furthermore, analysis of the gene expression signatures of
these soft tissue tumors in a breast carcinoma expression
dataset has suggested that there may be molecularly distinct
patterns of stromal reaction in breast cancer. These stromal
reaction patterns appear to be correlated with differences in
the biology of the tumors that are reﬂected in clinical
outcome.
Figure 5. Hierarchical Clustering of 295 Breast Carcinomas with 471 SFT and DTF Genes
Within the heatmap, red represents high expression, black represents median expression, and green represents low expression. Sidebar on right
indicates which tumor the gene is positively associated with: pink is SFT and purple is DTF. Sidebar on left indicates gene cluster. Gene array
data are available at http://microarray-pubs.stanford.edu/tma-portal/DTF_SFTbreast.
DOI: 10.1371/journal.pbio.0030187.g005
PLoS Biology | www.plosbiology.org June 2005 | Volume 3 | Issue 6 | e187 1107
Stromal Signatures in Breast CarcinomaFigure 6. Outcome Data
Statistical method of the y-axis is Kaplan-Meier survival curves compared by the Cox-Mantel log-rank test. The x-axis unit of measure is years.
(A) Time to ﬁrst recurrence for tumor group A versus all other tumors.
(B) Time to ﬁrst recurrence for tumor group B versus all other tumors.
(C) Survival outcome for tumor group A versus all others.
(D) Survival outcome for tumor group B versus all others
DOI: 10.1371/journal.pbio.0030187.g006
Table 2. Multivariate Analysis for Tumor Group Status versus Clinical Risk Factors including Treatment with Chemotherapy, Tumor Size
(,2 cm), Lymph Node Status, Tumor Grade (Low and Intermediate versus High), Age (,40 y old), Vascular Invasion
Cox Regression Analysis Group and
Clinical Risk Factors on Survival
Risk Factor Statistical
Significance
Hazard Ratio 95.0% CI
Lower Upper
Group A ChemoTx 0.355 1.386 0.694 2.768
Tumor size 0.036 1.663 1.034 2.676
LN status 0.622 1.181 0.61 2.284
Grade 0.001 2.308 1.41 3.779
Age 0.012 0.543 0.337 0.876
Vascular 0.009 1.379 1.085 1.752
Group A 0.021 0.549 0.33 0.915
Group B ChemoTx 0.174 1.629 0.806 3.292
Tumor size 0.076 1.551 0.954 2.52
LN status 0.382 1.345 0.691 2.618
Grade 0.013 1.934 1.15 3.255
Age 0.013 0.547 0.339 0.882
Vascular 0.001 1.502 1.178 1.916
Group B 0.0002 2.62 1.577 4.353
Group B and ‘‘70 genes’’ ChemoTx 0.18 1.624 0.799 3.298
Tumor size 0.045 1.635 1.011 2.644
LN status 0.55 1.225 0.629 2.385
Grade 0.284 1.327 0.791 2.226
Age 0.082 0.653 0.404 1.056
Vascular 0.004 1.444 1.128 1.848
‘‘70 genes’’ ,0.0001 5.249 2.284 12.059
Group B 0.016 1.859 1.124 3.075
The hazard ratio for death, CI, and statistical significance are included. The ‘‘70 genes’’ factor refers to the 70 genes previously published to be predictive in the 295 breast carcinomas dataset [15].
ChemoTx, chemotherapy; LN, lymph node.
DOI: 10.1371/journal.pbio.0030187.g002
PLoS Biology | www.plosbiology.org June 2005 | Volume 3 | Issue 6 | e187 1108
Stromal Signatures in Breast CarcinomaMaterials and Methods
Tumor samples for DTF and SFT cDNA microarray analysis.
Tumors were collected from four academic institutions (Vancouver
General Hospital, Cleveland Clinic Foundation, University of
Washington Medical Center, and Stanford University Medical Center)
with IRB approval. After resection, a representative sample was
quickly frozen and stored at  80 8C. Prior to processing, frozen
sections of the tissue were cut and histologically examined to ensure
that the tissue represented the diagnostic entity. The DTFs were all
sporadic cases, including ﬁve cases from the extremities, two cases
from the abdomen, two cases from the sacrum, and one case from the
chest wall. The SFTs included 13 cases with benign features; all but
one were derived from the chest cavity. SFT cases with malignant
pathologic or clinical features were excluded. The diagnoses were
based on clinical data, morphologic data, and IHC, including CD34
(Table S2).
DTF and SFT cDNA microarray procedures. We used 42,000-spot
cDNA microarrays to measure the relative mRNA expression levels in
the tumors. The details of isolating mRNA, labeling, and hybridizing
are described elsewhere [11]. The raw data ﬁles are available at
Stanford Microarray Database (http://genome-www5.stanford.edu/);
the ﬁltered data used for the paper are available at the accompanying
Web site (http://microarray-pubs.stanford.edu/tma-portal/
DTF_SFTbreast). Data were ﬁltered using the following criteria:
Only cDNA spots with a ratio of signal over background of at least 1.5
in both the Cy3 and the Cy5 channel were included; only cDNAs were
selected that had an absolute value at least four times greater in at
least two arrays than the geometric mean; and only cDNA spots that
fulﬁll these criteria on at least 70% of the arrays were included. Data
were evaluated with unsupervised hierarchical clustering and SAM
[13].
Analysis of breast carcinoma dataset. The gene array dataset for
breast carcinoma contained 295 tumors arrayed on 25,000-spot oligo
nucleotide arrays as described elsewhere [15]. In short, patients were
all diagnosed and treated in the Netherlands Cancer Institute for
early breast cancer (Stage I and II) between 1984 and 1995. The
median follow-up for living patients is 7.8 y. Additional clinical data
can be found in Table S3.
For DTF and SFT, genes were identiﬁed that were highly expressed
in either of the two tumor types by using SAM [13]. A total of 1,010
spots satisﬁed the gene-ﬁltering criteria mentioned above in the
clustering of the DTF and SFT tumors. The criterion for SAM was set
to yield 0.1% false-positive data. A list of 786 clones was obtained that
consisted of 493 genes positively identifying ﬁbromatosis and 293
genes positively identifying SFT. Equal numbers of DTF and SFT
clones were chosen for breast carcinoma analysis, and clones having
the same Unigene locus were removed, resulting in 237 unique gene
sequences identifying DTF and 246 unique gene sequences identify-
ing SFT. These gene sequences were mapped to spots on the NKI
array using Unigene build 172 (release date 17 July 2004) to give 471
unique spots. Gene measurements were mean centered. The resulting
dataset was subjected to hierarchical clustering with average linkage
clustering.
Overall survival (OS) was deﬁned by death from any cause. In this
cohort of young breast cancer patients, only six patients died of
causes other than breast cancer (ﬁve second primaries and one
cardiovascular). Distant metastasis-free survival (DMFS) was deﬁned
by a distant metastasis as a ﬁrst recurrence event; data on all patients
were censored on the date of the last follow-up visit, death from
causes other than breast cancer, the recurrence of local or regional
disease, or the development of a second primary cancer, including
contra-lateral breast cancer. Kaplan-Meier survival curves were
compared by the Cox-Mantel log-rank test in Winstat for Microsoft
Excel (R. Fitch Software, Germany). Multivariate analysis by the Cox
proportional hazard method was performed using the software
package SPSSt 11.5 (SPSS, Inc.).
TMA construction. A TMA of ﬁbroblastic conditions was con-
structed using a manual tissue arrayer (Beecher Instruments, Silver
Spring, Maryland, United States) following previously described
techniques [23] with modiﬁcations. Brieﬂy, certain specimens, such
as skin and ﬁstula tract, contained tissues whose positional
orientation was important for analysis. Coring of these tissues could
lose orientation of the cells within the core. Therefore, orientation-
sensitive material was dissected from the original blocks and re-
embedded into the parafﬁn block used for tissue arraying. Tissues
thus embedded included skin, lung, breast, granulation tissue, and
ﬁstula tract (see Figure S2). After the embedding process was
completed, construction of the tissue array was performed using
single 2-mm cores. In addition, the TMA contained 0.6-mm cores of
lobular (n = 14) and ductal (n = 10) breast carcinomas, ﬁbroade-
nomas (n = 11), SFT (n = 5), DTF (n = 5), and colorectal carcinomas
(n = 2), scar (n = 1), and keloid (n = 1). All samples were obtained
from archived material at the Stanford University Medical Center
Department of Pathology between 2001 and 2004 with IRB approval.
The cores were taken from areas in the parafﬁn block that were
representative of the diagnostic tissue.
IHC. Serial sections of 4 lm were cut from the TMA blocks,
deparafﬁnized in xylene, and hydrated in a graded series of alcohol.
The slides were pretreated with citrate buffer and a microwave step.
Staining was then performed using the DAKO EnVisionþ System,
Peroxidase (DAB), (DAKO, Cambridgeshire, United Kingdom) for
APOD (Clone 36C6, 1:40 dilution, Novocastra, Newcastle, United
Kingdom), CD34 (1:20 dilution, BD Biosciences, San Diego, California,
United States), and BCL2 (1:800 dilution, DAKO Cytomation,
Carpinteria, California,United States)stains. Resultswere interpreted
asfollows:Stainingwasinterpretedasnegativewhennomorethan5%
of the spindled stromal cells showed light staining. A score of ‘‘weak
positive’’ was given for light-brown staining in more than 5% of the
spindled stromal cells. A score of ‘‘strong positive’’ was given for
staininginmorethan50%ofthespindledstromalcells.Coresinwhich
nodiagnosticmaterialwaspresentwereomittedfromfurtheranalysis.
The cores were initially reviewed independently by two pathologists
(RW and MvdR), and disagreements were reviewed together to achieve
a consensus score. Scoring of the arrays was analyzed using the
Deconvoluter software as previously described [24], with each sample
receiving the highest score for either of the two cores.
In situ hybridization (ISH). ISH of TMA sections was performed
based on a protocol published previously [23,25]. Brieﬂy, digoxigenin
(DIG)-labeled sense and anti-sense RNA probes are generated by PCR
ampliﬁcation of 400 to 600 bp products with the T7 promoter
incorporated into the primers. In vitro transcription was performed
with a DIG RNA-labeling kit and T7 polymerase according to the
manufacturer’s protocol (Roche Diagnostics, Indianapolis, Indiana,
United States). We cut sections 4 lm thick from the parafﬁn blocks,
d e p a r a f ﬁ n i z e dt h e mi nx y l e n e ,a n dh y d r a t e dt h e mi ng r a d e d
concentrations of ethanol for 5 min each. Sections were then
incubated with 3% hydrogen peroxide, followed by digestion in 10
lg/ml of proteinase K at 37
oC for 30 min. Sections were hybridized
overnight at 55
oC with either sense or anti-sense riboprobes at 150
ng/ml dilution in mRNA hybridization buffer (DAKO). The following
day, sections were washed in 23 SSC and incubated with a 1:35
dilution of RNase A cocktail (Ambion, Austin, Texas, United States)
in 23SSC for 30 min at 37
oC. Next, sections were stringently washed
in 23 SSC/50% formamide twice, followed by one wash at 0.083 SSC
at 50
oC. Biotin blocking reagents (DAKO) were applied to the section
to block the endogenous biotin. For signal ampliﬁcation, a HRP-
conjugated rabbit anti-DIG antibody (DAKO) was used to catalyze the
deposition of biotinyl tyramide, followed by secondary streptavidin
complex (GenPoint kit; DAKO). The ﬁnal signal was developed with
DAB (GenPoint kit; DAKO), and the tissues were counterstained in
hematoxylin for 15 s. The primer sequences used for the ampliﬁca-
tion of probes for OSF2, CTHRC1, and APOD are given in Table S4.
Supporting Information
Figure S1. Soft Tissue Tumor Gene Expression of Ten Cases of DTF
and 13 Cases of SFT
The DTF cases (blue) and the SFT cases (orange) are based on
expression proﬁling on 42,000-element cDNA microarrays.
Found at DOI: 10.1371/journal.pbio.0030187.sg001 (1.6 MB JPG).
Figure S2. Low-Power Image of TMA with Oriented Fragments of
Tissue (and Cores
The oriented fragments of tissue are show at the bottom of the ﬁgure;
the cores are shown at the top
Found at DOI: 10.1371/journal.pbio.0030187.sg002 (683 KB JPG).
Figure S3. Fibroblastic Markers in Non-Neoplastic Tissue
(A) Skin adnexa, (B) breast, (C) dermis, (D) reactive, and (E) keloid
tissue arranged in rows. Fibroblastic markers: CD34 (IHC), APOD
(ISH), CTHRC1 (ISH), and OSF2 (ISH) arranged in columns. SFTs
express APOD and CD34 whereas DTFs express CTHRC1 and OSF2.
Magniﬁcation = 3003.
Found at DOI: 10.1371/journal.pbio.0030187.sg003 (7.0 MB JPG).
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Stromal Signatures in Breast CarcinomaTable S1. Signiﬁcance Analysis of Microarray (SAM)
SFT and DTF are analyzed with a false discovery rate of 0.1%.
Found at DOI: 10.1371/journal.pbio.0030187.st001 (1.0 MB XLS).
Table S2. Clinical Information for DTF and SFT Cases
Found at DOI: 10.1371/journal.pbio.0030187.st002 (17 KB XLS).
Table S3. Clinical Data on the 295 Breast Carcinoma Case Set from
the Netherlands Cancer Institute
Found at DOI: 10.1371/journal.pbio.0030187.st003 (131 KB XLS)
Table S4. Primer Sequences Used for the Ampliﬁcation of Probes for
ISH
Found at DOI: 10.1371/journal.pbio.0030187.st004 (17 KB PDF).
Accession Numbers
The Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/) GeneID acces-
sion numbers for the genes and gene products discussed in this paper
are, APOD (GeneID 347), BCL2 (GeneID 596), CD34 (GeneID 947),
COL9A3 (GeneID 1299), CTHRC1 (GeneID 115908), OSF2 (GeneID
10631), and THY1 (GeneID 7070).
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